Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Craven House Capital ( (GB:CRV) ) has issued an update.
Craven House Capital PLC’s unaudited interim report for the six months ended November 30, 2024, reveals a modest operating profit of $37,000, despite a loss of $2,000 for the period. The company received a significant share distribution from RoseMonkey Ltd, increasing its stake in QuiaPeg Pharma AB to 23.2%. The report highlights the company’s strategic focus on maintaining and managing its investment portfolio, with valuations of certain private investee companies held at zero due to their pre-revenue status. This financial update underscores the company’s cautious approach in navigating its investments, with implications for stakeholders regarding its strategic positioning in the pharmaceutical and eCommerce sectors.
More about Craven House Capital
Craven House Capital PLC is an investment company listed on the AIM Market of the London Stock Exchange, focusing on early-stage investments primarily in the pharmaceutical and eCommerce sectors. The company holds shares in two quoted pharmaceutical companies in Stockholm and maintains minority stakes in five private Swedish-managed businesses.
YTD Price Performance: 10.0%
Average Trading Volume: 12,233
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.06M
For an in-depth examination of CRV stock, go to TipRanks’ Stock Analysis page.